Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

CSL Behring Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (77)
Prescription medicine registration (4)
Designation or determination (3)
Australian public assessment report (AusPar) (1)
Section 14, TGO91 consent (1)

Date

2025 (1)
2024 (2)
2023 (4)
2022 (10)
2021 (2)
2020 (3)
2019 (9)
2018 (4)
2017 (3)
2016 (2)
2015 (46)

Search

Sponsor content

86 result(s) found, displaying 51 to 60

CSL MALAYSIA Intrapure Normal Immunoglobulin (Human) 6% (6g/100mL), solution for intravenous infusion Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Korea Commercial Aleviate, Human Coagulation Factor VIII for Injection 250 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Korea Commercial Aleviate, Human Coagulation Factor VIII for Injection 500 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Indonesia Commercial Aleviate, Human Coagulation Factor VIII for Injection 250 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Indonesia Commercial Aleviate, Human Coagulation Factor VIII for Injection 500 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Korea Commercial Biostate, Human Coagulation Factor VIII for Injection 250 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Korea Commercial Biostate, Human Coagulation Factor VIII for Injection 500 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Biostate Europe, Human Coagulation FVIII/VWF complex 500 IU (50 IU/mL) Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Biostate Europe, Human Coagulation FVIII/VWF complex 1000 IU (100 IU/mL) Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd
CSL Indonesia Commercial Biostate, Human Coagulation Factor VIII for Injection 250 IU Cancelled under Section 30(1)(c) of the Act

29 June 2015

Cancellation by sponsor

Requested by CSL Behring Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.